Management change in Vaccibody AS
649
post-template-default,single,single-post,postid-649,single-format-standard,bridge-core-1.0.4,ajax_updown_fade,page_not_loaded,,qode-title-hidden,qode-child-theme-ver-,qode-theme-ver-18.2.1,qode-theme-bridge,disabled_footer_top,qode_header_in_grid,wpb-js-composer js-comp-ver-6.0.5,vc_responsive

Management change in Vaccibody AS

As Vaccibody is entering into a new development phase, the Board of Directors has initiated a search process for a new CEO with experience from clinical development and strategic partnering. On this background, Ole Henrik Brekke, CEO since 2006, has decided to leave the company. Chairman of the board, Tom Pike, will serve as Acting CEO until a new CEO is in place. The board would like to thank Dr. Brekke for his contribution to the considerable progress the company has made under his leadership since its inception.